CD19-TriCAR SILK cell therapy - Timmune Biotech
Alternative Names: CD19-TriCAR-SILK - Timmune BiotechLatest Information Update: 28 May 2022
At a glance
- Originator Timmune Biotech
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Leukaemia(Combination therapy, In adolescents, In children, Second-line therapy or greater) in China (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, In adolescents, In children, Second-line therapy or greater) in China (IV, Infusion)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, In the elderly, Second-line therapy or greater, In adults) in China (IV, Infusion)